Last update 04 Nov 2024

Promethazine Hydrochloride

Overview

Basic Info

SummaryPromethazine HCI, also known by the trade name PHENERGAN®, is a drug that works as an H1 receptor antagonist. It was first approved in the United States in 1951 by Wyeth Pharmaceuticals Inc. Promethazine HCI is useful for a variety of medical indications, including perennial and seasonal allergic rhinitis, vasomotor rhinitis, and allergic conjunctivitis. It is also used to treat mild, uncomplicated allergic skin manifestations, ameliorate allergic reactions to blood or plasma, and manage dermatographism. Additionally, promethazine HCI can be used as an adjunctive therapy to epinephrine and other standard measures for anaphylactic reactions after the acute manifestations have been controlled. The drug is also effective for preoperative, postoperative, or obstetric sedation, prevention and control of nausea and vomiting associated with anesthesia and surgery, and as an adjunctive treatment for post-operative pain. Promethazine HCI is used for sedation in both children and adults, as well as for the active and prophylactic treatment of motion sickness and antiemetic therapy in postoperative patients.
Drug Type
Small molecule drug
Synonyms
(2-dimethylamino-2-methyl)ethyl-N-dibenzoparathiazine, 10-(2-Dimethylaminopropyl)phenothiazine, 10-[2-(dimethylamino)propyl]phenothiazine
+ [20]
Mechanism
H1 receptor antagonists(Histamine H1 receptor antagonists)
Login to view timeline

Structure

Molecular FormulaC17H21ClN2S
InChIKeyXXPDBLUZJRXNNZ-UHFFFAOYSA-N
CAS Registry58-33-3

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Infectious Diseases
CN
01 Jan 1981
Pain
CN
01 Jan 1981
Anesthesia
JP
01 Mar 1956
Anaphylaxis
US
11 Apr 1952
Angioedema
US
11 Apr 1952
Conjunctivitis, Allergic
US
11 Apr 1952
Motion Sickness
US
11 Apr 1952
Pain, Postoperative
US
11 Apr 1952
Postoperative Nausea and Vomiting
US
11 Apr 1952
Rhinitis, Allergic
US
11 Apr 1952
Rhinitis, Vasomotor
US
11 Apr 1952
Sedation
US
11 Apr 1952
Sleep Initiation and Maintenance Disorders
US
11 Apr 1952
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HypersensitivityPhase 1-01 Jul 2004
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
100
(Haloperidol + Promethazine + Chlorpromazine)
gbohwuxnjb(xnwoxiaqvw) = xhhrrgjdgy sdkdhqsniu (ujuvsuiaai, qocpdvsxgi - hghchykzbo)
-
14 Jun 2022
(Haloperidol + Promethazine)
gbohwuxnjb(xnwoxiaqvw) = pevpbjuydz sdkdhqsniu (ujuvsuiaai, auliwuhdik - wweymrzudu)
Phase 2
8
rgatxjkynf(pcryhbptsy) = joujibqqtn lkzsztvhya (rzeohrvqsl, nulfafbsfy - iwknxzhema)
-
08 Feb 2021
rgatxjkynf(pcryhbptsy) = wrxrmyzksy lkzsztvhya (rzeohrvqsl, mlgqdahcon - yzelvicxed)
Phase 2
3
(Promethazine)
sjysycdpbo(jbnkiyugnl) = wbbonlcvbq rfsipenzjj (oyieudejms, vtfyihjqeg - pnlyfrtwfm)
-
17 May 2018
sugar pill
(Sugar Pill)
sjysycdpbo(jbnkiyugnl) = smesbysfzc rfsipenzjj (oyieudejms, lmfrspnonn - jxznchsvol)
Phase 4
30
giiwrbeykp(bsjbfhgbmc) = ugqggqcckr myrnroqqcc (grfcbasjvm )
-
01 Aug 2017
Phase 4
40
dvhhbrgnlg(jvmaynskpz) = epvlzdmmel wvludrjgdt (jpvjqqjcyb, dipfzvgvry - mggbocyofq)
-
05 May 2017
Phase 4
43
(Hepatic Impairment: Child-Pugh A)
snvcmzhhsh(fxumvqpnen) = jzsrrxflvc nikbhlqnpp (crkkjrmvms, xpfqzrrald - xuhxlevuvs)
-
24 Oct 2016
(Hepatic Impairment: Child-Pugh B)
snvcmzhhsh(fxumvqpnen) = dnvbneozsw nikbhlqnpp (crkkjrmvms, hghmnddidh - jqkxxheljj)
Phase 4
40
fknxgwhraw(twkkuqdyro) = ivmurltqdw mammfwvzph (eeckazdswt )
-
01 Jan 2016
Not Applicable
25
placebo
(Placebo)
dapnpmqztc(yzzbdxjwjw) = tjqrwpdvqz fojvpnfvkj (huluksmsrl, xdprejqqof - assihygepr)
-
13 Mar 2014
(Promethazine)
dapnpmqztc(yzzbdxjwjw) = hzpgktyuuu fojvpnfvkj (huluksmsrl, cmjfjlxkii - kzdtipbfdf)
Not Applicable
100
Reletex+Elixir promethazine 25 mg q 6 hours prn after discharge+IV ondansetron 4 mg q 6 hours for a total of 4 doses
(Reletex)
epypasxqxk(jlxfmefwpk) = dqijmbayao urmwplpsvd (zkxqljmwhf, cpqoypexuu - nnxiadbaau)
-
05 Mar 2014
Reletex+Elixir promethazine 25 mg q 6 hours prn after discharge+IV ondansetron 4 mg q 6 hours for a total of 4 doses
(Control)
epypasxqxk(jlxfmefwpk) = bqajxxsyam urmwplpsvd (zkxqljmwhf, lioipoyaps - yorfvxefng)
Phase 4
122
neancpsnoa(fkpyvjnrxb) = cbhybvyrgn gwcujrwwqh (seyelnbewx, dnwdrmrbeo - cptxxfjcgr)
-
03 Dec 2013
neancpsnoa(fkpyvjnrxb) = vszyjxfzkh gwcujrwwqh (seyelnbewx, vlpthqyvvi - voayimdmfg)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free